Invesco Ltd. reduced its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 74.6% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,108 shares of the company's stock after selling 41,380 shares during the quarter. Invesco Ltd.'s holdings in Kiniksa Pharmaceuticals were worth $279,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Wells Fargo & Company MN raised its stake in Kiniksa Pharmaceuticals by 54.7% in the fourth quarter. Wells Fargo & Company MN now owns 21,102 shares of the company's stock valued at $417,000 after purchasing an additional 7,463 shares in the last quarter. ExodusPoint Capital Management LP increased its holdings in shares of Kiniksa Pharmaceuticals by 965.2% in the 4th quarter. ExodusPoint Capital Management LP now owns 127,161 shares of the company's stock worth $2,515,000 after buying an additional 115,223 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Kiniksa Pharmaceuticals by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 492,630 shares of the company's stock valued at $9,744,000 after buying an additional 9,654 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Kiniksa Pharmaceuticals by 46.3% during the 4th quarter. Wellington Management Group LLP now owns 69,813 shares of the company's stock worth $1,381,000 after acquiring an additional 22,096 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Kiniksa Pharmaceuticals by 138.9% in the fourth quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock worth $9,451,000 after acquiring an additional 277,827 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.
Kiniksa Pharmaceuticals Price Performance
Kiniksa Pharmaceuticals stock traded down $0.83 during mid-day trading on Tuesday, reaching $26.95. 562,047 shares of the company traded hands, compared to its average volume of 480,096. The firm's 50 day moving average price is $22.07 and its 200 day moving average price is $21.34. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $17.38 and a 52-week high of $29.00. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -192.51 and a beta of 0.07.
Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. During the same period last year, the business posted ($0.25) earnings per share. Kiniksa Pharmaceuticals's quarterly revenue was up 72.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.
Insider Buying and Selling
In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,051 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the sale, the chief accounting officer now owns 26,528 shares in the company, valued at approximately $595,553.60. This represents a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the transaction, the chief operating officer now owns 81,975 shares of the company's stock, valued at $1,604,250.75. The trade was a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 224,820 shares of company stock valued at $5,386,361 over the last ninety days. Company insiders own 54.57% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on the company. Jefferies Financial Group upped their price objective on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Wedbush restated an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Finally, Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $38.80.
Get Our Latest Stock Analysis on Kiniksa Pharmaceuticals
About Kiniksa Pharmaceuticals
(
Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Recommended Stories
Before you consider Kiniksa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals wasn't on the list.
While Kiniksa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
